SSRIs Will Add Fetal Risk Information To Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is seeking additional information about the possible risk of persistent pulmonary hypertension in newborns.
You may also be interested in...
SSRI Safety During Pregnancy Questioned Anew In Studies
FDA is seeking data on how often antidepressants are used by pregnant women to help gauge the significance of the findings.
Paxil CR "Dear Doctor" Letter Reflects New Labeling On Birth Defects
Preliminary results from a retrospective epidemiologic study suggest an increased risk of congenital malformations associated with the use of paroxetine by pregnant women over other antidepressants, the letter states.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.